Pharmaxis Ltd (ASX:PXS, OTC:PMXSF) CEO Gary Phillips tells Proactive the company will add a combination treatment arm to the current Phase 2 clinical trial of PXS‐5505 in myelofibrosis following helpful feedback from the US FDA. He says they’re already in discussion with the existing trial site investigators who have welcomed the opportunity to extend the patient population for the study and anticipate significantly accelerated recruitment.
Pharmaxis to accelerate plans for myelofibrosis combination study after FDA talks
